[Site] This is the antibody combination drug we are currently implementing (R&D).
These are two drops of drugs, after instilling them, they will immediately improve the subject's immune level.
After instilling this infusion, inject this again.
[Explanation] Recently, the official website of the National Medical Products Administration issued a message to urgently approve the new coronavirus neutralizing antibody combination therapy drug Ambavirimab Injection (BRII-196) and Romisvirimab Injection (BRII-198) Application for registration.
It marks that China has the first fully self-developed and effective anti-coronavirus specific drug that has undergone strict randomized, double-blind, and placebo-controlled studies.
[Explanation] On December 9, Zhang Linqi, a professor at the School of Medicine of Tsinghua University, who led the research and development of the specific drug, gave a presentation to reporters.
Zhang Linqi said that specific drugs can reduce the hospitalization rate and mortality of high-risk new crown outpatients by 80%, and the main effect is treatment.
[Concurrent] Zhang Linqi, Professor, School of Medicine, Tsinghua University
Applicable populations are those with mild infection from the indications approved by it, but those at high risk of disease progression (high risk factors for progression to severe).
Including some people with underlying diseases, such as obesity, cardiovascular disease, and diabetes.
The age is over 18 years old (weight ≥40kg).
Between 12-18 years old (weight ≥40kg) is also possible, but it is only a condition for conditional listing (approval).
Antibodies can stay in the body for 9-12 months, and the ability to neutralize the virus is more than 400 times at 9 months.
[Explanation] Zhang Linqi introduced that the drug uses antibody combination therapy to enable the specific drug to identify different positions of the viral spike protein and perform "two-way clamping", thereby improving its effectiveness, safety and broad spectrum.
[Concurrent] Zhang Linqi, Professor, School of Medicine, Tsinghua University
Two (bottle) drugs accurately identify different targets, just like this protein.
This protein is a model, which is actually the spike protein on the surface of the virus.
Different colors indicate the positions recognized by different antibodies, (combined antibodies) can block the virus before it binds to the cells.
So the combination of two antibodies can increase its activity, which is the first advantage.
The second is that everyone knows that viruses are mutated now. The combination of two (bottle) drugs can not only inhibit the production of mutations, but also play a very big advantage in anti-mutant viruses, compared to a single drug.
Our drugs have outstanding characteristics in terms of activity, broad spectrum and sustainability.
[Explanation] The team is currently advancing the emergency use authorization of this combination therapy in the United States.
In the next step, the R&D team will continue to study the preventive effect of monoclonal antibody combination therapy in high-risk and immunodeficiency populations.
[Concurrent] Zhang Linqi, Professor, School of Medicine, Tsinghua University
Is it possible for us to take the first step in clinical treatment, especially prevention, instead of treating after infection?
Therefore, in terms of prevention research, we will start researching in the next step.
So as a researcher, what do we expect?
Whether these antibody drugs or vaccines are in our hands, they must be developed to the extreme.
Not only is it efficient, broad-spectrum, and sustainable, but it can also benefit more people all over the world. So we are still on the road in this regard, and we are continuing to work hard.
Reporting from Beijing by reporter Cheng Yu
Editor in charge: 【Luo Pan】